Targeting survivin with Tanshinone IIA inhibits tumor growth and overcomes chemoresistance in colorectal cancer

被引:8
|
作者
Cao, Yaoquan [1 ]
Tang, Haibo [1 ]
Wang, Guohui [1 ]
Li, Pengzhou [1 ]
Song, Zhi [1 ]
Li, Weizheng [1 ]
Sun, Xulong [1 ]
Zhong, Xiaoxiao [1 ]
Yu, Qianqian [1 ]
Zhu, Shaihong [1 ]
Zhu, Liyong [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Gen Surg, Changsha 410013, Peoples R China
关键词
STEM-CELLS; APOPTOSIS; CHEMOTHERAPY; RESISTANCE;
D O I
10.1038/s41420-023-01622-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The inhibitor of apoptosis protein survivin has a critical regulatory role in carcinogenesis and treatment tolerance in colorectal cancer (CRC). However, the targeted drugs for survivin protein are extremely limited. In the present research, we discovered that Tanshinone IIA (Tan IIA) played a dual regulatory role in inhibiting tumorigenesis and reversing 5-Fu tolerance via modulating the expression and phosphorylation of survivin in CRC cells. Mechanistically, Tan IIA suppressed the Akt/WEE1/CDK1 signaling pathway, which led to the downregulation of survivin Thr34 phosphorylation and destruction of the interaction between USP1 and survivin to promote survivin ubiquitination and degradation. Furthermore, Tan IIA significantly facilitated chemoresistant CRC cells to 5-Fu sensitivity. These results revealed that Tan IIA possessed a strong antitumor activity against CRC cells and could act as an up-and-coming agent for treating CRC and overcoming chemotherapy resistance.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer
    Sui, Hua
    Zhao, Jihui
    Zhou, Lihong
    Wen, Haotian
    Deng, Wanli
    Li, Chunpu
    Ji, Qing
    Liu, Xuan
    Feng, Yuanyuan
    Chai, Ni
    Zhang, Qibo
    Cai, Jianfeng
    Li, Qi
    CANCER LETTERS, 2017, 403 : 86 - 97
  • [32] Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy
    Alam, Syed Sahajada Mahafujul
    Samanta, Arijit
    Uddin, Faizan
    Ali, Safdar
    Hoque, Mehboob
    PHARMACOLOGICAL REPORTS, 2023, 75 (04) : 907 - 922
  • [33] Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy
    Syed Sahajada Mahafujul Alam
    Arijit Samanta
    Faizan Uddin
    Safdar Ali
    Mehboob Hoque
    Pharmacological Reports, 2023, 75 : 907 - 922
  • [34] Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo
    Pierce, Marquicia R.
    Robinson, Reeder M.
    Ibarra-Rivera, Tannya R.
    Pirrung, Michael C.
    Dolloff, Nathan G.
    Bachmann, Andre S.
    LEUKEMIA RESEARCH, 2020, 88
  • [35] Tanshinone IIA Inhibits Osteosarcoma Growth through a Src Kinase-Dependent Mechanism
    Hu, Chao
    Zhu, Xiaobin
    Zhang, Taogen
    Deng, Zhouming
    Xie, Yuanlong
    Yan, Feifei
    Cai, Lin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [36] Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro
    Zhang, Zhaoxia
    Wang, Tianyou
    Liu, Ziqin
    Tango, Suoqin
    Yue, Mei
    Feng, Shunqiao
    Hu, Mengze
    Xuan, Litian
    Chen, Yanfei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (01) : 35 - 42
  • [37] Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis
    Liu, Jia-Jun
    Zhang, Yong
    Lin, Dong-Jun
    Xiao, Ruo-Zhi
    ONCOLOGY REPORTS, 2009, 21 (04) : 1075 - 1081
  • [38] Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer
    Masoud, Rawand
    Reyes-Castellanos, Gabriela
    Lac, Sophie
    Garcia, Julie
    Dou, Samir
    Shintu, Laetitia
    Hadi, Nadine Abdel
    Gicquel, Tristan
    El Kaoutari, Abdessamad
    Dieme, Binta
    Tranchida, Fabrice
    Cormareche, Laurie
    Borge, Laurence
    Gayet, Odile
    Pasquier, Eddy
    Dusetti, Nelson
    Iovanna, Juan
    Carrier, Alice
    CELL REPORTS MEDICINE, 2020, 1 (08)
  • [39] Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer
    Zhu, Yuanyuan
    Wang, Changying
    Li, Mingqun
    Yang, Xiaoyu
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2021, 73 (10) : 1418 - 1426
  • [40] Targeting GIPC/Synectin in Pancreatic Cancer Inhibits Tumor Growth
    Muders, Michael H.
    Vohra, Pawan K.
    Dutta, Shamit K.
    Wang, Enfeng
    Ikeda, Yasuhiro
    Wang, Ling
    Udugamasooriya, D. Gomika
    Memic, Adnan
    Rupashinghe, Chamila N.
    Baretton, Gustavo B.
    Aust, Daniela E.
    Langer, Silke
    Dam, Kaustubh
    Simons, Michael
    Spaller, Mark R.
    Mukhopadhyay, Debabrata
    CLINICAL CANCER RESEARCH, 2009, 15 (12) : 4095 - 4103